Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation

Junpei Koge, Hiroshi Yamagami, Kazunori Toyoda, Masahiro Yasaka, Teruyuki Hirano, Toshimitsu Hamasaki, Takehiko Nagao, Shinichi Yoshimura, Masahito Fujishige, Akira Tempaku, Shinichiro Uchiyama, Etsuro Mori, Masatoshi Koga, Kazuo Minematsu

Research output: Contribution to journalArticlepeer-review


Background The optimal timing of initiating oral anticoagulants after reperfusion therapy for ischemic stroke is unknown. Factors related to early initiation of rivaroxaban and differences in clinical outcomes of stroke patients with nonvalvular atrial fibrillation (NVAF) who underwent reperfusion therapy was investigated. Methods From data of 1,333 NVAF patients with ischemic stroke or transient ischemic attack (TIA) in a prospective multicenter study, patients who started rivaroxaban after intravenous thrombolysis and/or mechanical thrombectomy were included. The clinical outcomes included the composite of ischemic events (recurrent ischemic stroke, TIA, or systemic embolism) and major bleeding at 3 months. Results Among the 424 patients, the median time from index stroke to starting rivaroxaban was 3.2 days. On multivariable logistic regression analysis, infarct size (odds ratio [OR], 0.99; 95% CI, 0.99-1.00) was inversely and successful reperfusion (OR, 2.13; 95%CI, 1.24-3.72) was positively associated with initiation of rivaroxaban within 72 hours. 205 patients were assigned to the early group (< 72 hours) and 219 patients (≥ 72 hours) to the late group. Multivariable Cox regression models showed comparable hazard ratios between the two groups at 3 months for ischemic events (hazard ratio [HR], 0.18; 95%CI, 0.03-1.32) and major bleeding (HR, 1.80; 95%CI, 0.24-13.54). Conclusions Infarct size and results of reperfusion therapy were associated with the timing of starting rivaroxaban. There were no significant differences in the rates of ischemic events and major bleeding between patients after reperfusion therapy who started rivaroxaban < 72 hours and ≥ 72 hours after the index stroke.

Original languageEnglish
Article numbere0264760
JournalPloS one
Issue number4 April 2022
Publication statusPublished - 04-2022
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • General


Dive into the research topics of 'Early initiation of rivaroxaban after reperfusion therapy for stroke patients with nonvalvular atrial fibrillation'. Together they form a unique fingerprint.

Cite this